Report of the TFOS/ARVO symposium on global treatments for dry eye disease: An unmet need

Sullivan D.A., Hammitt K.M., Schaumberg D.A., Sullivan B.D., Begley C.G., Gjorstrup P., Garrigue J.-S., Nakamura M., Quentric Y., Barabino S., Dalton M., Novack G.D.

2012
Ocular Surface

View publication

Therapeutic Area

Front of the eye (FOTE)
Categories

Post-Approval studies/RWE

Affiliations

Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, 20 Staniford Street, Boston, 02114, MA, United States; Sjögren's Syndrome Foundation, Bethesda, MD, United States; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States; TearLab Corporation, San Diego, CA, United States; School of Optometry, Indiana University, Bloomington, IN, United States; Resolvyx Pharmaceuticals, Bedford, MA, United States; Novagali Pharma, Evry, France; Santen Pharmaceutical Co., Nara, Japan; Iris Pharma, La Gaude, France; Clinica Oculistica, Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy; Dalton and Associates, Reading, PA, United States; PharmadLogic, San Rafael, CA, United States

Related Publications

Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Ishikawa H., Oka K., Inoue H.

Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial

Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.

Layer-by-layer tear film measurement in patients with dry eye and meibomian gland dysfunction

Arita R., Takeuchi G., Sasai K., Nakamura M., Akiba M.